Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × lenvatinib × Clear all

Phase

Phase 1 11 Phase 2 6 Phase 1/2 5 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5 Liver Neoplasms 2 Neoplasms 1 Hepatoblastoma 1 Hepatitis B 1 Advanced Non-small Cell Lung Cancer 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 pertuzumab 2 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Trastuzumab 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Dexmedetomidine 2 Ciprofloxacin 2 vedolizumab 1 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡